Catálogo de productos [{"id":"463","name":"Evaluation of Parsaclisib plus Bendamustine and Rituximab in patients with Newly Diagnosed Mantle Cell Lymphoma","price":1,"sku":"lymphoma-trial-2","brand":false,"position":1,"category":"Medicines\/| Clinical Trials"},{"id":"462","name":"Evaluation of Tafasitamab plus Rituximab and Lenalidomide in patients with Lymphoma that has stopped responding to treatment","price":1,"sku":"lymphoma-trial-3","brand":false,"position":2,"category":"Medicines\/| Clinical Trials"},{"id":"461","name":"Evaluation of Parsaclisib plus Rituximab or Obinutuzumab in patients with Lymphoma that has stopped responding to treatment","price":1,"sku":"lymphoma-trial-4","brand":false,"position":3,"category":"Medicines\/| Clinical Trials"},{"id":"460","name":"Evaluation of Tafasitamab plus Parsaclisib in patients with Non Hodgkin Lymphoma or Chronic Lymphocytic Leukemia","price":1,"sku":"lymphoma-leukemia-trial-1","brand":false,"position":4,"category":"Medicines\/| Clinical Trials"},{"id":"459","name":"Evaluation of Parsaclisib plus Ruxolitinib in patients with Myelofibrosis who have not responded to Ruxolitinib alone","price":1,"sku":"myelofibrosis-trial-1","brand":false,"position":5,"category":"Medicines\/| Clinical Trials"},{"id":"458","name":"Evaluation of Nivolumab plus Docetaxel in men with Prostate Cancer","price":1,"sku":"prostate-cancer-trial-1","brand":false,"position":6,"category":"Medicines\/| Clinical Trials"}]

Opciones de acceso a los medicamentos

  1. Zejula
    Zejula (niraparib)
    Cáncer ginecológico
    €5,986.42
  2. Xeljanz
    Xeljanz (tofacitinib)
    Artritis reumatoide
    €1,198.35
  3. Tymlos
    Tymlos (abaloparatide)
    Osteoporosis
    €3,220.00
  4. Tecentriq
    Tecentriq (Atezolizumab)
    Carcinoma urotelial, cáncer de mama, cáncer de pulmón
    €7,452.90
  5. Taltz
    Taltz (ixekizumab)
    Psoriasis
    €3,185.16
  6. Tagrisso
    Tagrisso (osimertinib)
    Cáncer de pulmón
    €6,838.00
  7. Spinraza
    Spinraza (Nusinersen)
    Atrofia muscular espinal
    Precio disponible a petición
  8. Rydapt
    Rydapt (midostaurin)
    Leucemia
    €18,846.76
  9. Rubraca
    Rubraca (rucaparib)
    Cáncer ginecológico
    €2,021.44
  10. Portrazza
    Portrazza (necitumumab)
    Cáncer de pulmón
    €9,241.93
  11. Perjeta
    Perjeta (Pertuzumab)
    Cáncer de mama
    €3,036.09
Ver como Cuadrícula Lista

Artículos 1-12 de 349

Establezca la dirección de descenso
EE.UU. 0